Drug Test Kit Standards and Validation Rules

Ask AI

BFAD BUREAU CIRCULAR NO. 03, S. 2004: Drug Test Kit Standards and Validation Rules

Getting related questions...
What do you want to know about the law?
Your conversations and searches stay on your device. We do not store or track your activity on our servers. To know more about our privacy commitment see jur.ph/privacy Ask AI provides quick answers grounded in full case texts to avoid mistakes. Always verify with the original text.

Ask AI

Title Supreme Court: Drug Test Kit Standards and Validation Rules

Law: Bfad Bureau Circular No. 03, S. 2004

Decision Date: Mar 26, 2004

The Bureau of Food and Drugs (BFAD) establishes guidelines for the registration and performance validation of methamphetamine (MET) and tetrahydrocannabinol (THC) drug screening test kits, designating the East Avenue Medical Center as the National Reference Laboratory for evaluations, while extending the validity of existing certificates for certain drug tests.

administrative law

dangerous drugs

A

Designation of National Reference Laboratory

The East Avenue Medical Center (EAMC) is designated as the National Reference Laboratory (NRL).
EAMC is responsible for conducting performance evaluations of drug screening test kits and reagents.
Initially, EAMC will evaluate MET and THC test kits by non-instrumental methods only.

Transitional Provisions for Validation Certificates

Certificates of validated MET/THC drug screening test kits issued by the Dangerous Drugs Board are extended until April 15, 2004.
Certificates of validated drug screening kits for other substances such as Opiates, Cocaine, and Barbiturates, among others, are indefinitely extended until further notice.

Compliance and Sanctions

All concerned parties must comply with these guidelines.
Any violations of the guidelines will result in sanctions imposed by BFAD.
Sanctions ensure adherence to the regulatory framework for public safety and health.

Administrative Details

Issued through Bureau Circular No. 03, Series of 2004, dated March 26, 2004.
Authored and signed by Prof. Leticia-Barbara B. Gutierrez, M.S., Director of BFAD.
The circular informs and guides industry stakeholders on regulatory compliance related to drug screening test kits containing MET and THC.

END